Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease

ARYA Atherosclerosis

Volumn 7, Issue 3, 2011, Pages 106-110

  Akhlaghi, Arash ^a   Shirani, Shahin ^b   Ziaie, Naghmeh ^b   Pirhaji, Omid ^b   Yaran, Majid ^c   Shahverdi, Golnoosh ^b   Sarrafzadegan, Nizal ^a   Khosravi, Alireza ^d   Khosravi, Elham ^d  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clopidogrel; Coronary Artery Disease; CYP2C19; Iran; Polymorphism

Indexed keywords

EID: 84858128200     PISSN: 17353955     EISSN: 22516638     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bolognese L. Changing patterns of ST elevation myocardial infarction epidemiology. Am Heart J 2010; 160(6 Suppl): S1-3.
2. Abdallah M, Karrowni W, Shamseddeen W, Itani S, Kobeissi L, Ghazzal Z, et al. Acute coronary syndromes: clinical characteristics, management, and outcomes at the American University of Beirut Medical Center, 2002-2005. Clin Cardiol 2010; 33(1): E6-E13.
3. Donyavi T, Naieni KH, Nedjat S, Vahdaninia M, Najafi M, Montazeri A. Socioeconomic status and mortality after acute myocardial infarction: a study from Iran. Int J Equity Health 2011; 10(1): 9.
4. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A. Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 2007; 7: 32.
5. Terkelsen CJ, Sorensen JT, Maeng M, Jensen LO, TH, Trautner S, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 2010; 304(7): 763-71.
6. Lambert L, Brown K, Segal E, Brophy J, Rodes- Cabau J, Bogaty P. Association between timeliness of reperfusion therapy and clinical outcomes in STelevation myocardial infarction. JAMA 2010; 303(21): 2148-55.
7. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331(8): 496-501.
8. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331(8): 489-95.
9. Sutton JM, Ellis SG, Roubin GS, Pinkerton CA, King SB, Raizner AE, et al. Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation 1994; 89(3): 1126-37.
10. Cohen M. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheter Cardiovasc Interv 2009; 74(4): 579-97.
11. American College of Cardiology, American Heart Association Task Force on Practice Guidelines. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv 2008; 71(1): E1-40.
12. Ma TK, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol 2011. [Epub ahead of print].
13. Price MJ, Tantry US, Gurbel PA. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y (12) inhibitors. Rev Cardiovasc Med 2011; 12(1): 1-12.
14. Bauer T, Bouman HJ, Van Werkum JW, Ford NF, Ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343(d4588).
15. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain- Appaix A, Barthélémy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic metaanalysis. J Am Coll Cardiol 2010; 56(2): 134-43.
16. Camilleri E, Jacquin L, Paganelli F, Bonello L. Personalized antiplatelet therapy: review of the latest clinical evidence. Curr Cardiol Rep 2011; 13(4): 296-302.
17. Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 2011. [Epub ahead of print].
18. Djaffar Jureidini I, Chamseddine N, Keleshian S, Naoufal R, Zahed L, Hakime N. Prevalence of CYP2C19 polymorphisms in the Lebanese population. Mol Biol Rep 2011. [Epub ahead of print].
19. Zendehdel N, Biramijamal F, Hossein-Nezhad A, Zendehdel N, Sarie H, Doughaiemoghaddam M, et al. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis. Arch Iran Med 2010; 13(5): 406-12.
20. Zand N, Tajik N, Moghaddam AS, Milanian I. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol 2007; 34(1-2): 102-5.
21. Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57(11): 1251-63.
22. Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute STElevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 2011; 123(5): 474-82.
23. Huang CC, Chen YC, Leu HB, Chen TJ, Lin SJ, Chan WL, et al. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Am J Cardiol 2010; 105(12): 1705-9.
24. Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010; 3(6): 556-66.
25. Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 2011; 57(1): 86-93.
26. Cuisset T, Quilici J, Cohen W, Fourcade L, Saut N, Pankert M, et al. Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. Am J Cardiol 2011. [Epub ahead of print].
27. Park KW, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart 2011; 89(7):641-7.